Brookline notes that Adial announced the award of a patent covering the combination of the company’s genetic diagnostic test to identify patients with specific genotypes for genetically targeted treatment of alcohol use disorder and drug dependencies with AD04. Adial believes the new patent increases the potential for partners to engage with the company in the future, according to the analyst, who reiterates a Buy rating and $26 price target on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ADIL:
- Adial Pharmaceuticals awarded patent notice of allowance for USPTO
- Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office
- Adial Pharmaceuticals appoints Goodman as Chief Operating Officer
- Adial Announces Appointment of Tony Goodman as Chief Operating Officer
- Adial Pharmaceuticals files $100M mixed securities shelf